Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.76 and traded as high as $7.09. Achieve Life Sciences shares last traded at $7.06, with a volume of 136,545 shares trading hands.
Analysts Set New Price Targets
ACHV has been the topic of several analyst reports. Maxim Group reiterated a “buy” rating and issued a $8.00 target price on shares of Achieve Life Sciences in a research note on Friday, March 17th. Oppenheimer reiterated an “outperform” rating and issued a $17.00 target price on shares of Achieve Life Sciences in a research note on Friday, March 17th.
Achieve Life Sciences Price Performance
The firm has a 50 day simple moving average of $5.28 and a 200-day simple moving average of $3.76. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.01. The company has a market cap of $126.59 million, a PE ratio of -1.74 and a beta of 1.51.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last issued its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.07. During the same period in the previous year, the business posted ($0.76) EPS. As a group, research analysts predict that Achieve Life Sciences, Inc. will post -1.94 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Achieve Life Sciences
A number of large investors have recently modified their holdings of the business. Long Focus Capital Management LLC grew its stake in shares of Achieve Life Sciences by 73.6% during the third quarter. Long Focus Capital Management LLC now owns 308,220 shares of the biopharmaceutical company’s stock worth $1,017,000 after acquiring an additional 130,624 shares during the last quarter. LPL Financial LLC grew its stake in shares of Achieve Life Sciences by 48.4% during the fourth quarter. LPL Financial LLC now owns 148,300 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 48,400 shares during the last quarter. Raymond James & Associates grew its stake in shares of Achieve Life Sciences by 412.0% during the fourth quarter. Raymond James & Associates now owns 89,249 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 71,818 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Achieve Life Sciences by 57.5% during the second quarter. Renaissance Technologies LLC now owns 39,700 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 14,500 shares during the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of Achieve Life Sciences by 33.2% during the third quarter. Citadel Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 8,725 shares during the last quarter. Hedge funds and other institutional investors own 21.11% of the company’s stock.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
See Also
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.